Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D E White

Showing results (31-40 of 63) with videos related to

Pageof 7
Sort By:
JPEN. Journal of Parenteral and Enteral Nutrition|May 1, 1987
Water-soluble vitamins in cancer patients on parenteral nutrition: a prospective studyR I Inculet, J A Norton, G E Nichoalds, et al.
The Journal of Urology|July 4, 2001
Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinomaJ R Vasselli, J C Yang, W M Linehan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1992
The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphomaJ S Weber, J C Yang, S L Topalian, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|January 1, 1996
Combination therapy with interferon-gamma and interleukin-2 for the treatment of metastatic melanomaC J Kim, J K Taubenberger, T B Simonis, et al.
Journal of Surgical Oncology|August 1, 1989
Extremity soft tissue sarcomas: analysis of prognostic variables in 300 cases and evaluation of tumor necrosis as a factor in stratifying higher-grade sarcomasE E Lack, S M Steinberg, D E White, et al.
Cancer|December 15, 1994
Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinomaR L White, D J Schwartzentruber, A Guleria, et al.
Annals of Internal Medicine|June 1, 1987
Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancerA Belldegrun, D E Webb, H A Austin, et al.
Annals of Surgery|October 1, 1989
Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patientsS A Rosenberg, M T Lotze, J C Yang, et al.
Archives of Surgery (Chicago, Ill. : 1960)|December 1, 1986
Prospective study of cardiomyopathy induced by adjuvant doxorubicin therapy in patients with soft-tissue sarcomasS E Ettinghausen, R O Bonow, S T Palmeri, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|November 1, 1995
Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 aloneR S Krouse, R E Royal, G Heywood, et al.
Pageof 7

Showing results (31-40 of 63) with videos related to

Sort By:
Pageof 7
JPEN. Journal of Parenteral and Enteral Nutrition|May 1, 1987
Water-soluble vitamins in cancer patients on parenteral nutrition: a prospective studyR I Inculet, J A Norton, G E Nichoalds, et al.
The Journal of Urology|July 4, 2001
Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinomaJ R Vasselli, J C Yang, W M Linehan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1992
The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphomaJ S Weber, J C Yang, S L Topalian, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|January 1, 1996
Combination therapy with interferon-gamma and interleukin-2 for the treatment of metastatic melanomaC J Kim, J K Taubenberger, T B Simonis, et al.
Journal of Surgical Oncology|August 1, 1989
Extremity soft tissue sarcomas: analysis of prognostic variables in 300 cases and evaluation of tumor necrosis as a factor in stratifying higher-grade sarcomasE E Lack, S M Steinberg, D E White, et al.
Cancer|December 15, 1994
Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinomaR L White, D J Schwartzentruber, A Guleria, et al.
Annals of Internal Medicine|June 1, 1987
Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancerA Belldegrun, D E Webb, H A Austin, et al.
Annals of Surgery|October 1, 1989
Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patientsS A Rosenberg, M T Lotze, J C Yang, et al.
Archives of Surgery (Chicago, Ill. : 1960)|December 1, 1986
Prospective study of cardiomyopathy induced by adjuvant doxorubicin therapy in patients with soft-tissue sarcomasS E Ettinghausen, R O Bonow, S T Palmeri, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|November 1, 1995
Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 aloneR S Krouse, R E Royal, G Heywood, et al.
Pageof 7